In vivo graft manipulation with antithymocyte globulin (ATG) [7–13] or alemtuzumab [14] and ex vivo graft manipulation with CD34 selection and T cell depletion [15–19] are strategies that are associated with lower rates of chronic GVHD. The gene discussed is CD34; the disease is chronic graft versus host disease.